The performance of companies tied to Sildenafil's legacy presents a challenging investment scenario . While the initial surge generated substantial profits , generic alternatives have significantly eroded revenue. Investing in related pharmaceutical businesses now requires a discerning assessment of patent protection , evolving patient trends , and